Innoviva
Innoviva is committed to building long-lasting value and improving patient care.
Launch date
Employees
Market cap
€1.1b
Enterprise valuation
€1.3b (Public information from Sep 2024)
Share price
$19.54 INVA
Burlingame California (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 337m | 392m | 331m | 310m | 339m | 341m | 369m |
| % growth | 29 % | 16 % | (15 %) | (6 %) | 9 % | 1 % | 8 % |
| EBITDA | 322m | 373m | 216m | 224m | 180m | 162m | 164m |
| % EBITDA margin | 96 % | 95 % | 65 % | 72 % | 53 % | 47 % | 44 % |
| Profit | 224m | 266m | 214m | 180m | - | - | - |
| % profit margin | 67 % | 68 % | 65 % | 58 % | - | - | - |
| EV / revenue | 4.1x | 3.5x | 3.5x | 4.1x | 4.2x | 3.9x | 3.3x |
| EV / EBITDA | 4.3x | 3.7x | 5.5x | 5.7x | 7.8x | 8.1x | 7.4x |
| R&D budget | 1.8m | <1m | 41.4m | 33.9m | - | - | - |
| R&D % of revenue | 1 % | - | 13 % | 11 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | N/A | IPO | |
* | N/A | $225m | Post IPO Debt |
* | $1.9m | Post IPO Equity | |
| Total Funding | - | ||
Related Content
Recent News about Innoviva
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Innoviva
Edit
ACQUISITION by Innoviva Aug 2022
ACQUISITION by Innoviva May 2022
exited
